Car-T Cell Therapy: Current Advances and Future Research Possibilities

M. M. Ahmed
{"title":"Car-T Cell Therapy: Current Advances and Future Research Possibilities","authors":"M. M. Ahmed","doi":"10.47631/jsrmbs.v2i2.234","DOIUrl":null,"url":null,"abstract":"Purpose: The aim is to review the current advances in designing safer and more efficient CAR-T cells and discuss the future research possibilities for the treatment of both hematological malignancies and solid tumors.\nStudy Design: An extensive review was carried out on the basic structure of CARS, current advances to design safer and more efficient CAR-T cells, and future research possibilities for the treatment of both hematological malignancies and solid tumors.\nResults: Encouragement of chimeric antigen receptor-T (CAR-T) cell therapy as one of adoptive immunotherapy is increasingly important in recent years. Its preparation is based on the genetic modification of individual T cells. The innovation of the functional intracellular signaling domain is a critical part of the genetically modified T cells and requires a long journey of development that has resulted in several improvements in the safety and effectiveness of CAR-T cells. CAR-T cell therapy can be modified rapidly and has great and strong application potential according to a large number of global clinical trials. This article briefly describes the basic structure and design of CARs and discusses current trends in the development of safer and more efficient CAR-T cells for the treatment of both hematological and solid malignancies and looks forward to future research possibilities.\nConclusion: It is concluded that conclude that the prospect of this technology lies in CAR-T cell engineering which can overcome aggressive TMEs and recruiting an endogenous tumor response. The final task for researchers in this field is to carry out clinical trials and secure the funding needed to complete their clinical trials. This immunotherapy continues to progress and more records of successful malignancy eradication occur.","PeriodicalId":422270,"journal":{"name":"Journal of Scientific Research in Medical and Biological Sciences","volume":"14 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Scientific Research in Medical and Biological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47631/jsrmbs.v2i2.234","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Purpose: The aim is to review the current advances in designing safer and more efficient CAR-T cells and discuss the future research possibilities for the treatment of both hematological malignancies and solid tumors. Study Design: An extensive review was carried out on the basic structure of CARS, current advances to design safer and more efficient CAR-T cells, and future research possibilities for the treatment of both hematological malignancies and solid tumors. Results: Encouragement of chimeric antigen receptor-T (CAR-T) cell therapy as one of adoptive immunotherapy is increasingly important in recent years. Its preparation is based on the genetic modification of individual T cells. The innovation of the functional intracellular signaling domain is a critical part of the genetically modified T cells and requires a long journey of development that has resulted in several improvements in the safety and effectiveness of CAR-T cells. CAR-T cell therapy can be modified rapidly and has great and strong application potential according to a large number of global clinical trials. This article briefly describes the basic structure and design of CARs and discusses current trends in the development of safer and more efficient CAR-T cells for the treatment of both hematological and solid malignancies and looks forward to future research possibilities. Conclusion: It is concluded that conclude that the prospect of this technology lies in CAR-T cell engineering which can overcome aggressive TMEs and recruiting an endogenous tumor response. The final task for researchers in this field is to carry out clinical trials and secure the funding needed to complete their clinical trials. This immunotherapy continues to progress and more records of successful malignancy eradication occur.
Car-T细胞疗法:目前的进展和未来的研究可能性
目的:回顾目前在设计更安全、更有效的CAR-T细胞方面的进展,并讨论未来治疗血液系统恶性肿瘤和实体肿瘤的研究可能性。研究设计:对CAR-T细胞的基本结构、设计更安全、更有效的CAR-T细胞的最新进展以及治疗血液系统恶性肿瘤和实体肿瘤的未来研究可能性进行了广泛的回顾。结果:鼓励嵌合抗原受体- t (CAR-T)细胞疗法作为过继性免疫疗法之一,近年来越来越受到重视。它的制备是基于对单个T细胞的基因改造。功能性细胞内信号域的创新是基因修饰T细胞的关键部分,需要漫长的发展历程,这导致了CAR-T细胞的安全性和有效性的几次改进。全球大量临床试验表明,CAR-T细胞疗法可以快速修饰,具有巨大而强大的应用潜力。本文简要介绍了CAR-T细胞的基本结构和设计,讨论了目前开发更安全、更有效的CAR-T细胞治疗血液病和实体恶性肿瘤的趋势,并展望了未来的研究可能性。结论:该技术的前景在于CAR-T细胞工程,它可以克服侵袭性TMEs并募集内源性肿瘤反应。该领域研究人员的最后一项任务是开展临床试验并获得完成临床试验所需的资金。这种免疫疗法继续取得进展,并且出现了更多成功根除恶性肿瘤的记录。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信